Maria Artunduaga, Samay - Acoustic Resonance Technology for Respiratory Patients | LSI USA '24

Maria Artunduaga  0:02  
Good morning, everybody. I'm Dr Maria Artunduaga. I'm the founder and CEO of Samay, a company that is building an AI patch for COPD diagnosis and management. The company was inspired after personal tragedy tragedy when I lost my grandmother to respiratory attack as COPD exacerbation. And ever since I've made it my life's mission to solve a problem that took her life away. After her passing, I realized that COPD is actually a massive problem. It affects 30 million Americans today we spent $61 billion taking care of these patients and about 40% of those expenses are going into exacerbations. Or in companies have successfully this disrupted the diagnostic market already. We have Dexcom with diabetes and Ireland with Brittany as both companies sold four point 6,500,000,000 in 2023. In terms of market sizing, if you think about it, COPD patients are about twice the number of insulin dependent diabetics and 14 times more of patients with atrial fibrillation. So we think we could even be more successful than them because we are truly disrupting the status quo. The standard of care today, believe it or not our question nurse subjective data that's missing 50% of exacerbation events, driving about 700,000 hospitalizations every single year from COPD. What is it that makes us special? Why are so different? i Why are we so different from our competitors. So let's talk about the long the longest oriented, it's full of air and we are using acoustics to make it resonate. We make the long thing we understand it's time bird and sound quality. And we can understand how the how the lung is functioning. And more importantly, we can detect changes. We use very complicated mathematics and algorithms to predict the numbers coming out from the hospital machine. And let me tell you a little secret very people knew very few people know this. There is a very good it's the strongest prognosticator for all things that go wrong with COPD, namely exacerbations, mortality, quality of life and tolerance to exercise, that it's called air trapping. air trapping is a parameter that can only damage be measured at the hospital by doing CT scan, or uplift is pulmonary function testing or plethysmography machine. And we can do this net right now from home. air trapping. What it is, is an abnormal accumulation of air at the most distal part of the obstructed region of the lung that it's disease. And that's what we are doing right now we are building an end to end the Raha platform that can monitor the trapping and many other parameters passively. We want to enable clinicians to understand lung function to monitor and especially to detect lung function decline earlier enough so that we can enable interventions to triaging patients helping clinicians to intervene earlier prevent costly hospitalizations. We do this just like many other companies during other fields such as CHF, for example, we have a chest patch that goes on the thorax, it stays there for about two weeks, we are sending the signals, we detect those changes, we send everything to an app and then to upload a form to the cloud on our platform that analyzes everything in real time, we have seven granted patents, on the way how we use acoustics to detect detect air trapping. So far, so far, we've tested the technology on 300 people, we can diagnose COPD with 90% of accuracy, error trapping with 83% of accuracy, and we can detect changes of medication efficacy with 80% of accuracy. We are already surpassing the standard of care questionnaires. By 60%. In a bottom up marker approach, we calculate a market opportunity of about 6.6 billion, starting with life science companies at risk providers taking care of patients that are frequently exacerbating and they are doing remote patient monitoring, and obviously hospital readmission programs. If we wanted to go further into the different markets in the future, we could go we could do hospitals, home programs, consumers and obviously payers and employers. We have two initial business models the typical life science as a research tool using an FDA registered product $1,000 per patient per month, and our fighting kick your device that will sell to remote patient monitoring companies charging about $60 per patient per month, we could make up to 720 per year with a gross margins of about 70% Because our cost of goods are really really low. We're sensor it's about $40. In when we are manufacturing it the potential for additional indications is about 12 billion just in the US think of asthma cystic fibrosis, pulmonary fibrosis, all of them actually Harvard shopping as a strong prognosticator, also out there to say that the next frontier for the next 2020 to 30 years is actually respiratory, not cardiac. Thanks to climate change and air pollution 10% of the world population is going to be affected with chronic respiratory conditions by 2050. There are many competitors in the market, of course, because this is a real big important problem, of course, but we are very differentiated not only because we have patents, but because we do think so different. We passively monitor function of the lung, we don't follow signs or symptoms such as coughing or wheezing that clinically are not as relevant. And we don't use a spiral metric that has so many challenges for patients. The adherence wears pyrometry, about 60 to 70%. Just once a week, and more importantly, replicability is a big issue with a spider amatory, most of these patients will require 30% of them to go to the hospital to do the right and you need supervision all the time. So I'm Dr. Moriarty Dragon, I lead some ice team, physician trained at Harvard and UC Berkeley. I lead NIH and gates funded projects in the past. I have published in the New England Journal medicine, nature, I'm PNAS. Ricardo Garcia. He's a Googler, whose code runs on 3 billion devices worldwide every day since graduating from MIT, we have a team of 14 developers and clinical researchers working full time with us, and about 15 contractors and consultants who have taken products through the FDA and sold millions in health care. We've raised about $4 million, already half of its coming from brands and we expecting about $5 million more in non diluted funding within the next 12 months. This is our timeline for the next 12 months. We are expecting to generate revenue by next year in 12 months with a class register product that will help us develop our sales and marketing strategy. At the same time that we are collecting a lot of data from patients that will probably monitor and ideally obviously a class two by the end of 2026 with a monitoring indication showing acoustic frequency data to remote patient monitoring companies. So obviously we are here because we are fundraising we are we have 20% of our round committed already $5 million to hit all of his milestones. exacerbation trial, the patch to be finalized probably one to $2 million and research contracts. We have ello eyes for about 70 million in potential revenue for pharmaceuticals, and then an FDA submission. So if you're interested in talking to me learning more about the company, go to the app, look me up Moriarty and Wagga or you can email me to Maria at some eye health.com and I can send you a Calendly link. We can talk next week next week. Thank you